- Home
- FBK vs CDTX Comparison
FBK vs CDTX Comparison
Compare FBK & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBK | CDTX |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FBK | CDTX |
|---|---|---|
| Price | $56.87 | $220.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $61.25 | ★ $128.75 |
| AVG Volume (30 Days) | 285.3K | ★ 2.3M |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $462,659,000.00 | N/A |
| Revenue This Year | $26.58 | N/A |
| Revenue Next Year | $31.81 | N/A |
| P/E Ratio | $26.61 | ★ N/A |
| Revenue Growth | ★ 6.02 | N/A |
| 52 Week Low | $38.83 | $15.22 |
| 52 Week High | $60.52 | $221.20 |
Technical Indicators
Market Signals| Indicator | FBK | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.58 | 88.29 |
| Support Level | $55.16 | $219.36 |
| Resistance Level | $58.00 | $221.20 |
| Average True Range (ATR) | 1.42 | 0.95 |
| MACD | 0.36 | -1.18 |
| Stochastic Oscillator | 86.91 | 82.06 |
Price Performance
Historical ComparisonAbout FBK FB Financial Corporation
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.